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Abstract 
 Hepatocellular carcinoma (HCC) continues to be one of the leading causes of death 
among cancer patients worldwide. HCC occurs in well-defined at-risk populations, with curative 
therapy possible only for small tumors, making it a potential target for creating new screening 
techniques. Imaging in conjunction with serum biomarker measurements have been the hallmark 
of HCC diagnosis, but have shown limited use as a surveillance tool. An objective, GALAD 
score is a serum biomarker-based statistical model that predicts the probability of having HCC in 
patients with chronic liver disease. 
Consisting of gender, age, AFP, AFP-L3, and des-ɤ-carboxyprothrombin (DCP), the GALAD 
model improves upon prior biomarker measurements by analyzing an AFP glycoform more 
specific to malignant tumors and HCC inflammation, and a prothrombin precursor able to 
differentiate HCC from non-malignant liver disease. This retrospective study is focused on 
validating the use of the GALAD model as a potential HCC screening tool. Patients at risk for 
HCC who had AFP total & L3% and DCP measurements will be included in the study. HCC 
diagnosis will be made by imaging criteria and/or pathology when available. Etiologies of liver 
disease including hepatitis B, hepatitis C, alcohol, and non-alcoholic fatty liver disease will also 
be recorded. Comparison with existing GALAD model results will help demonstrate GALAD’s 
utility as an HCC screening tool in the San Diego and international populations.  
 
Background 
Hepatocellular carcinoma (HCC) ranks as one of the most common types of cancer 
worldwide, 5th among men and 9th among women, with highest incidence among individuals 
aged 30-50 particularly in low-income populations (Mittal 2013, Ferlay 2015). HCC represents a 
dire complication of cirrhosis with risk factors that include hepatitis B and C infection, alcohol, 
and non-alcoholic fatty liver diseases. From 2003-2012, HCC incidence and mortality increased 
by 38% and 56%, making it the second leading cause of death from cancer (Group 2016). Signs 
and symptoms of HCC include jaundice, ascites, weight loss, nausea, abdominal pain, fatigue, or 
thrombocytopenia manifesting as easy bruising; however, their late-onset and nonspecific nature 
decrease their utility as screening signs (R 1995, Chalasani N 1999, El-Serag HB 1999). 
However, if detected early, HCC can be potentially cured by surgical resection, liver 
transplantation or local ablation (Njei B 2015). Preventive efforts, screening, surveillance, and 
early diagnosis are most important to improve outcome for HCC patients (Schlageter M 2014). 
One randomized controlled trial from China showed HCC related mortality was reduced 
by 37% in the surveillance arm with ultrasound and AFP every 6 months compared to the control 
arm with no surveillance (Zhang BH 2004). Screening and surveillance are therefore 
recommended in high risk patients including cirrhosis from any etiology and certain HBV 
patients without cirrhosis (Bruix J 2011). The recommended screening tools include ultrasound 
with or without use of biomarker AFP. However, ultrasound has limited sensitivity of ~60% to 
detect early HCC, but it is the only imaging modality proven effective in a RCT, and the only 
imaging modality that is cost-effective (Yu NC 2011). 
 Unfortunately, AFP has poor sensitivity (41-65%) and specificity (80%) when used alone 
(Arrieta O 2007, ZHAO 2013). A literature review of studies investigating imaging alone and 
imaging in conjunction with serum biomarkers found the latter to be more cost-effective for 
identification of HCC amongst cirrhotic patients, and helped infer incidence, prevalence, and 
HCC risk factors (ZHAO 2013, Chang TS 2015). However, the large amount of resources 
utilized still yielded little benefit for overall patient survival (Ruggeri 2012, Chang TS 2015). 
The issues regarding cost, subjectivity, and level of expertise required to interpret images 
remained.  
Given HCC’s persistence, particularly in low-income areas, it has been imperative to 
develop and validate a new model for detection of HCC. Recently, a completely objective serum 
biomarker-based model for the detection of HCC was developed based on: gender, age, AFP, 
AFP-L3, and des-ɤ-carboxyprothrombin (Johnson PJ 2014, Berhane S 2016). Called “GALAD,” 
it has performed well in retrospective settings in patient cohorts with early disease (tumor size < 
5cm) as well as advanced disease. In all cohorts, the ability to discriminate patients with HCC 
from chronic liver disease and hepatobiliary disease patients (defined by AUROC) was greater 
than 0.90 (Berhane S 2016). These early studies have largely looked at patients from the UK, 
Germany, Japan, and Hong Kong. With further validation in an international setting, the 
GALAD model has the potential to be an objective, cost-effective tool in the 
screening/surveillance setting. Improved screening will in turn yield earlier treatment and better 
prognosis for HCC patients. 
 
Definition 
AFP has been the most widely used serum biomarker for the early detection of HCC 
(Arrieta O 2007, Rodriguez-Diaz JL 2007). It is a protein produced during the embryonic period 
by the visceral endoderm, and later by the liver. Increased AFP production in patients have been 
suggested to reflect abnormal or altered liver cell regeneration. AFP levels diagnostic for HCC, 
as defined by the American Association for the Study of Liver Diseases is a level >200ng/mL 
(Trape J 2003). While these guidelines have helped diagnose HCC, particularly when combined 
with US results, there are limitations. The positive rate of AFP in HCC is only 60-80% leading to 
many false-negatives, and AFP results may be positive in other states including pregnancy, 
active non-HCC liver disease, and certain embryonic and gastrointestinal tumors (Farinati F 
2006, Arrieta O 2007). Discovery of AFP heterogeneity and its three glycoforms (AFP-L1, AFP-
L2, and AFP-L3) may allow for increased sensitivity and specificity. Whereas AFP-L1 is a major 
glycoform in benign liver disease, AFP-L3 exists only in serum of HCC patients. Furthermore, it 
does not correlate with AFP allowing it to be used independently for early diagnosis of HCC 
(Singhal A 2012). 
The GALAD model was designed to make use of these serum biomarkers to better 
predict the probability of HCC in a patient at risk. Improving the ability to predict HCC would in 
turn lead to earlier diagnosis, therapy, and prognosis for a disease with growing mortality rates 
that is currently difficult to screen for. While early studies of GALAD have demonstrated its 
ability to discriminate patients with HCC from those with other liver pathology, the goal of this 
project is to validate the use of GALAD as a screening tool in a patient cohort in the United 
States (which may differ from previously studied cohorts in demographics, etiology, risk factors, 
etc). Additionally, we will aim to do further analysis to compare with imaging results with LI-
RADS (the Liver Imaging Reporting and Data System), prediction of macrovascular invasion. 
The student will perform an initial literature review relevant to the above goals. He will 
also complete the chart review in its entirety and be responsible for identifying and selecting the 
appropriate patients for inclusion. Additional duties will include participating in statistical 
analysis and interpretation of results with the help of the committee, organizing these results into 
a written form (abstract, poster, or manuscript) for final presentation. The proposed work will be 
carried out starting the summer of 2017 and finalized during the 2 months of ISP time during the 
fourth year of medical school.  
 
 
Methods 
The goals stated above were the foundation for the chart review. The retrospective 
medical chart review was conducted at UCSD Medical Center. Records for patients with chronic 
liver disease and AFP total, AFP L3%, and DCP measurements from March 2010 to January 
2016 were included in the study. Inclusion criteria included at least one set of serum triple tumor 
biomarkers, and imaging/clinical follow ups. Exclusion criteria included patients who had a 
history of prior HCC diagnosis (diagnosis >3 months prior to first biomarker measurements) and 
patients with non-HCC liver malignancy.  
 
Demographic data (age, gender) was recorded. Etiologies of liver disease including 
Hepatitis B (HBsAg and HBV DNA), Hepatitis C (HCV Ab and HCV RNA), alcohol abuse, 
non-alcoholic steatohepatitis, were recorded. Patients’ BMI (body mass index) and presence of 
type II diabetes mellitus were also recorded. Presence of HCC diagnosis, date of diagnosis and 
last clinic visits, imaging results with LI-RADS categorization, staging, pathology, and lab 
results for total AFP, AFP-L3, DCP at baseline and follow-up visits were recorded.  
 
GALAD scores (Z) were calculated using the following equation:  
𝑍 = 10.08 + 0.09 ∗ (𝑎𝑔𝑒) + 1.67 ∗ (𝑠𝑒𝑥) + 2.34 ∗ log10(𝑡𝑜𝑡𝑎𝑙 𝐴𝐹𝑃) 
+0.04 ∗ (𝐴𝐹𝑃𝐿3) + 1.33 ∗ log10(𝐷𝐶𝑃) 
 
where sex = 1 for male and 0 for female. HCC probability (PrHCC) were calculated based off the 
GALAD scores: 
𝑃𝑟𝐻𝐶𝐶 =
𝑒𝑍
1 +  𝑒𝑍
 
 
Data was collected from baseline until the end of the observation period (ie last visit) in 
the charts. The area under the receiver operating characteristic curves (AUROC) were generated 
first as a whole, then as subgroups according to LI-RADS category and etiology classifications. 
The 95% confidence intervals (CIs) for the AUROCs were constructed assuming a normal 
distribution for the area under the curve. 
 
 
Outcomes 
An initial analysis of 148 patient charts was performed, with the results summarized and 
discussed in an abstract submitted to and accepted for poster presentation at the AASLD The 
Liver Meeting in Washington, D.C. in October 2017 (poster copied after references).  
 
As part of the results, twenty patients were excluded due to other cancer diagnosis (n=3), prior 
diagnosis of HCC (n=16), and no adequate follow up (n=1). In the remaining 128 patients, there 
were 39 HCCs (6 biopsy proven, 26 LR 5, 1 LR 4, 6 LR 5v), and 89 patients without HCCs.  
GALAD sensitivity and specificity for HCC diagnosis was 69.2% and 91% respectively, with 
cutoff 0.689. Area under the receiver operating characteristic curve (AUROC) for GALAD for 
HCC diagnosis was 0.853, and for AFP, AFP-L3 and DCP was 0.764, 0.778, and 0.883 
respectively. 
AUROC was higher (p <0.05) in GALAD (0.857) compared to AFP (0.758) in early stage (T1, 
T2), but not significantly different from AFP-L3 (0.756) or DCP (0.784). There was no statistical 
difference among GALAD and each biomarker in late stage HCC (T3-T4) (GALAD 0.858, AFP 
0.785, AFP-L3 0.819, DCP 0.885). 
 
Review of an additional 560 patient charts was subsequently performed, with statistical analysis 
currently underway. 
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Use of GALAD in HCC Diagnosis: Relation to LI-RADS and Tumor Staging
Hepatocellular carcinoma (HCC) is the 2nd leading cause of cancer
death worldwide1, and the fastest cause of cancer death in the United
States.2
Screening and surveillance for HCC with biannual ultrasound is
recommended for high-risk patients to improve outcome by detecting
curable disease.3 Ultrasound may be limited in sensitivity however,
especially in obese patients.4
HCC diagnosis relies mainly on imaging. Liver Imaging Reporting and
Data System (LI-RADS) was created to standardize the reporting and
data collection of CT and MR imaging for HCC endorsed by the
American College of Radiology (ACR)..5
GALAD is a statistical model for estimating the likelihood of the
presence of hepatocellular carcinoma (HCC) in high-risk patients and
consists of age, gender, alfa fetoprotein (AFP), Lectin-reactive alpha-
fetoprotein (AFP-L3), and des-gamma-carboxy prothrombin (DCP).
Early international retrospective studies have demonstrated utility as a
screening tool in early disease.6,7
We aimed to investigate the performance of GALAD in HCC diagnosis,
stratified with LI-RADS and HCC staging, compared to that of the
individual biomarkers (AFP, AFP-L3, DCP).
Scott Nomura1, Cecilia Dalle Ore1, Yasuhiro Mori2, Hiroyuki Yamada2, Yuko Kono1
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• Performance of GALAD was significantly better for early stage HCC
(Stage T1 and T2) than AFP alone
• There was no significant difference between individual biomarker and
GALAD performance in advanced HCC (stage T3 or higher)
• GALAD performance was comparable to LI-RADS scores that
suggested HCC with vascular invasion
INTRODUCTION
• Patient charts with one or more measurement of AFP, AFP-L3 and DCP
from June 2011 to January 2016 at our institution were reviewed.
• AFP, AFP-L3 and DCP were measured by uTASWako i30 automated
analyzer (Wako Life Sciences, Inc. in Mountain View, CA USA)
• There were 16,068 measurements in 1766 patients. Preliminary
analysis in 394 measurements in 148 patients was performed.
• HCC diagnosis was established by biopsy or image findings using LI-
RADS (LI-RADS 5: definite HCC and LI-RADS 4: probable HCC, LI-
RADS 5V: tumor in vein) (Fig 1).
• GALAD scores (Z) were calculated using the following equation:
𝑍 = 10.08 + 0.09 ∗ 𝑎𝑔𝑒 + 1.67 ∗ 𝑠𝑒𝑥 + 2.34 ∗ log10 𝑡𝑜𝑡𝑎𝑙 𝐴𝐹𝑃
+0.04 ∗ 𝐴𝐹𝑃𝐿3 + 1.33 ∗ log10 𝐷𝐶𝑃
where sex = 1 for male and 0 for female. HCC probabilities (PrHCC) were
calculated based off the GALAD scores:
𝑃𝑟𝐻𝐶𝐶 =
𝑒𝑍
1 +  𝑒𝑍
• Each biomarker and GALAD score performance was compared among
LR (LI-RADS) 5, LR 4, LR 5V (tumor in vein), T staging, etiology, and
BMI.
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Twenty patients were excluded due to other cancer diagnosis (n=3), prior
diagnosis of HCC (n=16), and no adequate follow up (n=1). In the
remaining 128 patients, there were 39 HCCs (6 biopsy proven, 26 LR 5, 1
LR 4, 6 LR 5v), and 89 patients without HCCs.
GALAD sensitivity and specificity for HCC diagnosis was 69.2% and 91%
respectively, with cutoff 0.689. Area under the receiver operating
characteristic curve (AUROC) for GALAD for HCC diagnosis was 0.853,
and for AFP, AFP-L3 and DCP was 0.764, 0.778, and 0.883 respectively.
AUROC was
higher (p <0.05) in
GALAD (0.857)
compared to AFP
(0.758) in early
stage (T1, T2), but
not significantly
different from AFP-
L3 (0.756) or DCP
(0.784). There was
no statistical
difference among
GALAD and each
biomarker in late
stage HCC (T3-T4)
(GALAD 0.858,
AFP 0.785, AFP-
L3 0.819, DCP
0.885).
AUC: 0.853
GALAD score was higher for
more advanced T stage HCC
and highest in patients with
vascular invasion (LR-5V/
stage T4b). There was no
difference in etiology or BMI
in GALAD performance.
Early Stage (T1 & T2) Late Stage (T3-T4)
AFP
GALAD
AUC: 0.758 AUC: 0.785
AUC: 0.858AUC: 0.857
Fig. 1: LI-RADS v2014 used for HCC diagnosis5
• Limitations of generalizing our study include differences in patient
demographics, use of different staging criteria, and an unknown
performance as a prospective screening tool
• Review of 1616 additional charts will be included in future analysis
Patients 
(#, Location)
Sensitivity, 
%
Specificity, 
%
Cut-off 
Value
128, San Diego 69 91 0.689
1278, Germany6 88 88 -0.68
4476, Japan6 81 89 -1.95
670, United 
Kingdoms7
93 89 -0.63
Table 1: 
Comparison 
of GALAD 
performance. 
Our results in 
green.
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